Cytosorbents EBITDA Margin 2010-2024 | CTSO
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Cytosorbents (CTSO) over the last 10 years. The current EBITDA margin for Cytosorbents as of December 31, 2024 is .
| Cytosorbents EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-12-31 |
$0.04B |
$-0.01B |
-38.89% |
| 2024-09-30 |
$0.03B |
$-0.02B |
-62.50% |
| 2024-06-30 |
$0.03B |
$-0.02B |
-71.88% |
| 2024-03-31 |
$0.03B |
$-0.03B |
-83.87% |
| 2023-12-31 |
$0.03B |
$-0.03B |
-100.00% |
| 2023-09-30 |
$0.04B |
$-0.03B |
-75.00% |
| 2023-06-30 |
$0.04B |
$-0.03B |
-82.86% |
| 2023-03-31 |
$0.03B |
$-0.03B |
-91.18% |
| 2022-12-31 |
$0.03B |
$-0.03B |
-91.18% |
| 2022-09-30 |
$0.04B |
$-0.03B |
-94.44% |
| 2022-06-30 |
$0.04B |
$-0.03B |
-78.95% |
| 2022-03-31 |
$0.04B |
$-0.03B |
-64.29% |
| 2021-12-31 |
$0.04B |
$-0.02B |
-50.00% |
| 2021-09-30 |
$0.05B |
$-0.02B |
-33.33% |
| 2021-06-30 |
$0.05B |
$-0.01B |
-26.09% |
| 2021-03-31 |
$0.04B |
$-0.01B |
-22.73% |
| 2020-12-31 |
$0.04B |
$-0.01B |
-21.43% |
| 2020-09-30 |
$0.04B |
$-0.01B |
-32.43% |
| 2020-06-30 |
$0.03B |
$-0.02B |
-46.88% |
| 2020-03-31 |
$0.03B |
$-0.02B |
-53.57% |
| 2019-12-31 |
$0.02B |
$-0.02B |
-70.83% |
| 2019-09-30 |
$0.02B |
$-0.02B |
-73.91% |
| 2019-06-30 |
$0.02B |
$-0.02B |
-65.22% |
| 2019-03-31 |
$0.02B |
$-0.02B |
-69.57% |
| 2018-12-31 |
$0.02B |
$-0.02B |
-65.22% |
| 2018-09-30 |
$0.02B |
$-0.01B |
-63.64% |
| 2018-06-30 |
$0.02B |
$-0.01B |
-65.00% |
| 2018-03-31 |
$0.02B |
$-0.01B |
-61.11% |
| 2017-12-31 |
$0.02B |
$-0.01B |
-56.25% |
| 2017-09-30 |
$0.01B |
$-0.01B |
-71.43% |
| 2017-06-30 |
$0.01B |
$-0.01B |
-83.33% |
| 2017-03-31 |
$0.01B |
$-0.01B |
-110.00% |
| 2016-12-31 |
$0.01B |
$-0.01B |
-133.33% |
| 2016-09-30 |
$0.01B |
$-0.01B |
-125.00% |
| 2016-06-30 |
$0.01B |
$-0.01B |
-142.86% |
| 2016-03-31 |
$0.01B |
$-0.01B |
-150.00% |
| 2015-12-31 |
$0.01B |
$-0.01B |
-180.00% |
| 2015-09-30 |
$0.00B |
$-0.01B |
-225.00% |
| 2015-06-30 |
$0.00B |
$-0.01B |
-200.00% |
| 2015-03-31 |
$0.00B |
$-0.01B |
-175.00% |
| 2014-12-31 |
$0.00B |
$-0.01B |
-150.00% |
| 2014-09-30 |
$0.00B |
$0.00B |
-100.00% |
| 2014-06-30 |
$0.00B |
$0.00B |
-100.00% |
| 2014-03-31 |
$0.00B |
$0.00B |
-133.33% |
| 2013-12-31 |
$0.00B |
$0.00B |
-200.00% |
| 2013-09-30 |
$0.00B |
$0.00B |
-200.00% |
| 2013-06-30 |
$0.00B |
$0.00B |
-200.00% |
| 2013-03-31 |
$0.00B |
$0.00B |
-200.00% |
| 2012-12-31 |
$0.00B |
$0.00B |
-200.00% |
| 2012-09-30 |
$0.00B |
$0.00B |
-400.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED PRODUCTS |
$0.063B |
$0.036B |
|
CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company's product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey.
|
